{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:12:04Z","timestamp":1793995924329,"version":"4.8.0"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T00:00:00Z","timestamp":1435190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Merck, Sharp, & Dohme (MSD) Chibret Laboratories."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The ability to interpret scores from patient\u2010reported outcome measures at the individual patient level depends on the availability of valid, clinically meaningful benchmarks of response and state attainment. The goal was to develop multinational estimates for minimal clinically important improvement (MCII) and patient acceptable symptomatic state (PASS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multinational sample of patients with osteoarthritis (OA) was evaluated before and 4 weeks after treatment with nonsteroidal antiinflammatory drugs. Patients completed either the Western Ontario and McMaster Osteoarthritis Index (WOMAC) numerical rating scale 3.1 (hip and knee OA) or the Australian\/Canadian Index (AUSCAN) numerical rating scale 3.1 (hand OA) before and after treatment. Patients rated the clinical importance of their response to treatment and their satisfaction with the health state achieved, from which multinational MCII and PASS estimates were calculated for both the WOMAC and AUSCAN indices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 609 patients from 7 countries participated in the study. MCII and PASS estimates varied slightly by instrument and subscale. Absolute (percentage) change for MCII ranged 6\u20139 (10% to 17%) for WOMAC and 4\u20139 (8% to 15%) for AUSCAN. PASS estimates ranged 39\u201348 for WOMAC and 38\u201345 for AUSCAN. Some between\u2010country variation was observed in MCII and PASS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Preliminary multinational estimates for MCII and PASS have been developed for several countries. Further research is required to evaluate the robustness, temporal consistency, and age\u2010 and sex\u2010dependency of the preliminary estimates as well as their generalizability to other countries, languages, cultures, regions, and other condition\u2010specific outcome measures.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.22538","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T14:54:59Z","timestamp":1420642499000},"page":"972-980","source":"Crossref","is-referenced-by-count":96,"title":["Development of Multinational Definitions of Minimal Clinically Important Improvement and Patient Acceptable Symptomatic State in Osteoarthritis"],"prefix":"10.1002","volume":"67","author":[{"given":"Nicholas","family":"Bellamy","sequence":"first","affiliation":[{"name":"University of Queensland School of Medicine, Brisbane, Queensland, Australia, and Royal Brisbane and Women's Hospital Herston Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hochberg","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, INSERM, UMR\u2010S 1123, INSERM, CIC 1425\u2010EC, UMR\u2010S 1123, and AP\u2010HP H\u00f4pital Bichat Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Martin\u2010Mola","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz and Universidad Aut\u00f3noma Madrid Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassane","family":"Awada","sequence":"additional","affiliation":[{"name":"Saint Joseph University H\u00f4tel\u2010Dieu de France Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto General Research Institute, Institute for Work and Health, and Mount Sinai Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najia","family":"Hajjaj\u2010Hassouni","sequence":"additional","affiliation":[{"name":"Mohammed Vth Souissi University, CNRST, and Laboratory of Information and Research on Bone Diseases (LIRPOS\u2010URAC 30), Rabat, Morocco, and El Ayachi Hospital and University Hospital Sal\u00e9 Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Logeart","sequence":"additional","affiliation":[{"name":"Pfizer Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci\u2010Cerinic","sequence":"additional","affiliation":[{"name":"Denothe Centre University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart","family":"van de Laar","sequence":"additional","affiliation":[{"name":"Arthritis Center Twente Medisch Spectrum Twente, and University Twente Enschede The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"Paris Descartes University Cochin Hospital AP\u2010HP INSERM (U1153) PRES Sorbonne Paris\u2010Cit\u00e9 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(05)80101-3"},{"key":"e_1_2_7_3_1","first-page":"799","article-title":"Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: consensus development at OMERACT III","volume":"24","author":"Bellamy N","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_7_4_1","unstructured":"US Department of Health and Human Services. Food and Drug Administration. Guidance for industry. Patient\u2010reported outcome measures: use in medical product development to support labeling claims. URL:http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2000.0361"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2004.02.001"},{"key":"e_1_2_7_7_1","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities Osteoarthritis Index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich EW","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022905"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.026443"},{"key":"e_1_2_7_10_1","first-page":"501","article-title":"Response and state\u2010attainment criteria in hand OA: analyses from a placebo\u2010controlled clinical trial of CRX\u2010102, a novel synergistic combination therapy [abstract]","volume":"66","author":"Kvien TK","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"e_1_2_7_11_1","first-page":"S292","article-title":"Evaluation of clinically relevant changes and states in symptomatic outcome variables in osteoarthritis [abstract]","volume":"48","author":"Tubach F","year":"2003","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023028"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.04.004"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.07.011"},{"key":"e_1_2_7_15_1","first-page":"S69","article-title":"Prevalence of patients with low intensity pain symptom severity states during treatment with rofecoxib and ibuprofen for osteoarthritis [abstract]","volume":"12","author":"Bellamy N","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.03.002"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.03.003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00044-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21747"},{"key":"e_1_2_7_22_1","first-page":"95","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes following total hip or knee arthroplasty in osteoarthritis","volume":"1","author":"Bellamy N","year":"1988","journal-title":"J Orthop Rheumatol"},{"key":"e_1_2_7_23_1","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy N","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2002.0837"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2002.0838"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331101"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340502"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290816"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_7_31_1","first-page":"452","article-title":"Minimal clinically important difference module: summary, recommendations, and research agenda","volume":"28","author":"Wells G","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_7_32_1","first-page":"1110","article-title":"MCID\/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis","volume":"30","author":"Wells G","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_33_1","first-page":"1115","article-title":"MCID\/Low Disease Activity State Workshop: summary, recommendations, and research agenda","volume":"30","author":"Wells G","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015276414526"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199712060-00002"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00469-3"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22110"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090449"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22342"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23527"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20131"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22469"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2006.02.010"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22538","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:50:39Z","timestamp":1759416639000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,25]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/acr.22538"],"URL":"https:\/\/doi.org\/10.1002\/acr.22538","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,25]]}}}